Article
Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.
Medical oncology (Northwood, London, England) - 1 Sept 2012
Masago Katsuhiro, Togashi Yosuke, Fujita Shiro, Sakamori Yuichi, Okuda Chiyuki, Kim Young Hak, Mio Tadashi, Mishima Michiaki
Abstract excerpt
A study of patients with advanced non-squamous non-small cell lung cancer (NSCLC) evaluated epidermal growth factor receptor (EGFR) mutation status and serum hepatocyte growth factor (HGF) for their associations with response to gefitinib therapy and prognostic impact. An enzyme-linked immunosorbent assay was used to determine levels of HGF in serum from 96 Japanese patients with advanced non-squamous NSCLC. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.